GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » C-Rad AB (OSTO:CRAD B) » Definitions » Institutional Ownership

C-Rad AB (OSTO:CRAD B) Institutional Ownership : 7.89% (As of Jul. 06, 2025)


View and export this data going back to 2007. Start your Free Trial

What is C-Rad AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, C-Rad AB's institutional ownership is 7.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, C-Rad AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, C-Rad AB's Float Percentage Of Total Shares Outstanding is 0.00%.


C-Rad AB Institutional Ownership Historical Data

The historical data trend for C-Rad AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C-Rad AB Institutional Ownership Chart

C-Rad AB Historical Data

The historical data trend for C-Rad AB can be seen below:

2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31 2025-06-30
Institutional Ownership 12.42 10.90 9.90 9.56 9.57 9.59 7.76 7.77 7.83 7.89

C-Rad AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


C-Rad AB Business Description

Traded in Other Exchanges
Address
Sjukhusvagen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.

C-Rad AB Headlines

No Headlines